Tech and Web NEWS
GlaxoSmithKline’s pandemic H1N1 swine flu vaccine Pandemrix orders total 440m doses
By Bettina Padurano for CEOWORLD Magazine Updated:October 6, 2009
Get CEOWORLD Magazine digital monthly version. special- Top Capital Cities for a business Traveler, # Interview with Minister of Tourism of Greece. 1 Issues Subscription= $1 Only, 10 Issues Subscription= $5 Only. Grab your copy now!!!!
Pharmaceutical giant GlaxoSmithKline Plc (NYSE:GSK) said that governments around the world have so far ordered 440 million doses worth some $3.5 billion of its pandemic H1N1 swine flu vaccine Pandemrix.
GSK is among the companies that have begun shipping H1N1 vaccines and it anticipates this will continue through the fourth quarter of 2009 and the first half of next year. Since August 4 GSK has secured orders for 149m doses and is in talks with governments about further supplies.
This is generating substantial revenues for GSK. A deal with the US government is worth $250m but Reuters calculates, based on GSK’s figures and the sale cost of H1N1 vaccine, that the company’s total booked orders are worth £2.2bn.
Rivals in flu vaccines include Sanofi-Aventis (SASY.PA), Novartis (NOVN.VX), Baxter (BAX.N), AstraZeneca (AZN.L) and CSL (CSL.AX).
Like this article! |
|
|
|
|
(No Ratings Yet)
Loading ...171,533 views
Comments
Grab a copy of CEOWORLD Magazine for $1 only!!!
